Vitamin K Supplementation Guidelines for Children with Progressive Familial Intrahepatic Cholestasis (PFIC)

Pathophysiology & Risk of Deficiency

• Children with PFIC have cholestasis‑related fat malabsorption that prevents adequate dietary vitamin K uptake, making them intrinsically deficient regardless of oral intake. 1

Dosing Recommendations

Infants (< 12 months)

• Oral vitamin K₁ (phylloquinone) should be given at 0.3–1.0 mg daily, with the higher end (≈ 1 mg) preferred because of the severity of cholestasis in this age group. 1, 2

Children ≥ 1 year

• The standard maintenance dose is 5 mg vitamin K₁ daily; the dose may be increased to 10 mg daily for patients with persistent coagulopathy or documented low vitamin K levels. 1

General Administration Frequency

• Daily oral dosing is mandatory; weekly or intermittent regimens are ineffective because vitamin K has limited storage capacity and cholestasis impairs absorption even with daily dosing. 1

Formulation

• Only vitamin K₁ (phylloquinone) is acceptable for PFIC patients; menadione (vitamin K₃) salts must be avoided. 1

Monitoring Protocol

• Prothrombin time/INR should be measured at baseline, then every 3–6 months during stable maintenance therapy, and every 1–2 weeks after any dose adjustment or during acute illness. 3, 2

Drug Interactions & Pitfalls

• Cholestyramine can exacerbate vitamin K deficiency; it must be administered at least 2 hours apart from vitamin K dosing. 1, 3

Safety & Toxicity

• Vitamin K toxicity has not been reported within the recommended dosing range (up to 10 mg daily), allowing clinicians to prioritize adequacy without concern for overdose. 1

Special Situations

• During acute illness, antibiotic therapy, or peri‑operative periods, a temporary increase to 10 mg daily or a switch to parenteral (intravenous) vitamin K₁ should be considered. 1

Vitamin K Supplementation in Children

Introduction to Vitamin K Dosing

• The ESPEN-ESPGHAN-ECFS guidelines recommend a vitamin K dose of 1-10 mg/day for children beyond infancy, with the dose adjusted based on age and risk level 4, 5

Dosing Framework

• For routine supplementation in at-risk conditions, a standard dose of 1-5 mg/day is recommended for children with conditions predisposing to vitamin K deficiency, such as cystic fibrosis, fat malabsorption, or chronic antibiotic use 4, 5
• Consider 5-10 mg/day for children with documented low vitamin K levels, liver disease, severe malabsorption, or long-term broad-spectrum antibiotic therapy 4, 5

Form and Administration

• Vitamin K1 (phylloquinone) is the preferred and safest form for supplementation, superior to menadione salts 4, 5
• Daily administration is strongly preferred over weekly or intermittent dosing due to vitamin K's low storage capacity in the body 4, 5

Monitoring Considerations

• Measure vitamin K status when there is clinical suspicion of deficiency in conditions like cystic fibrosis, cholestasis, or unexplained bleeding 6
• PIVKA-II (protein induced by vitamin K absence) is the most sensitive marker for subclinical deficiency and should be used when available 4, 5, 6, 7, 8

Critical Clinical Pitfalls

• Do not use newborn/infant dosing (0.3-1 mg/day) for school-age children, as this is insufficient for older children 4, 5, 8
• Do not assume dietary intake is adequate in children with fat malabsorption, even if they consume green leafy vegetables, as absorption is impaired 4, 5

Evidence Quality and Guideline Strength

• The dosing recommendations are based on low-grade evidence, but the guidelines are clear that the dose should be age-appropriate and risk-stratified 4, 5
• Safety is not a concern at any dose within the recommended range, allowing clinicians to err on the side of adequacy 4, 5